672 related articles for article (PubMed ID: 11600369)
1. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
2. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.
Gould KA; Pan XS; Kerns RJ; Fisher LM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2108-15. PubMed ID: 15155208
[TBL] [Abstract][Full Text] [Related]
3. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
4. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
6. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the gyrB, parC, and parE genes of quinolone-resistant isolates and mutants of Edwardsiella tarda.
Kim MS; Jun LJ; Shin SB; Park MA; Jung SH; Kim K; Moon KH; Jeong HD
J Microbiol Biotechnol; 2010 Dec; 20(12):1735-43. PubMed ID: 21193831
[TBL] [Abstract][Full Text] [Related]
8. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
9. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
Pan XS; Fisher LM
J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
[TBL] [Abstract][Full Text] [Related]
10. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
[TBL] [Abstract][Full Text] [Related]
12. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
Heaton VJ; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance in Streptococcus pneumoniae from a university hospital, Thailand.
Srifuengfung S; Tribuddharat C; Chokephaibulkit K; Comerungsee S
J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S35-9. PubMed ID: 21298832
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
Zhou Y; Yu L; Li J; Zhang L; Tong Y; Kan B
Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
[TBL] [Abstract][Full Text] [Related]
18. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
Pan XS; Ambler J; Mehtar S; Fisher LM
Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
[TBL] [Abstract][Full Text] [Related]
19. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
Rafii F; Park M; Novak JS
Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
[TBL] [Abstract][Full Text] [Related]
20. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
Chen CR; Malik M; Snyder M; Drlica K
J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
